When a newborn baby takes her first breath she is already contaminated with a range of chemicals... this is the finding in the latest compelling research conducted by several leading authorities in the field of health and wellbeing. Raising awareness of toxic chemicals present in our everyday environment (food additives, personal care products, cleaning products etc.) and having the understanding that these chemicals, in most cases, are absorbed directly into the blood supply is fundamental to the health and wellbeing of our children and future generations. Most shocking from these latest findings is the fact that some of the chemicals found in newborn cord blood were banned decades ago!
Cholesterol-lowering statin drugs do not provide any protection against Alzheimer's disease, according to a study conducted by researchers from the Rush University Medical Center in Chicago and published in Neurology, the journal of the American Academy of Neurology.
"This study adds to the growing evidence that statins don't lower the risk of Alzheimer's disease," lead researcher Zoe Arvanitakis said. "The study also found no association between taking statins and a slower cognitive decline among older people."
The Food and Drug Administration will begin posting every three months a list of drugs whose safety is under investigation because of complaints brought to the agency's attention by drug companies, physicians and patients.
The FDA will name the drug and the nature of the "adverse events" but will not describe their seriousness or the number of complaints received, officials said yesterday.
Federal health authorities have asked the manufacturers of four widely used immunosuppressive drugs to bolster safety warnings on the risk of developing opportunistic fungal infections.
The drugs, Humira, Cimzia, Enbrel and Remicade, belong to a class of medications known as tumor necrosis factor alpha blockers (TNF-alpha blockers), which suppress the immune system and are approved to treat several conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis and Crohn's disease.
The higher proportion of deaths through five years was statistically significant only for the lowest dose of the drug called Fablyn, said Food and Drug Administration reviewers. More patients given Fablyn, which was co-developed with Ligand Pharmaceuticals Inc, also developed blood clots.
In an unprecedented change of posture, the New England Journal of Medicine has reversed itself on the issue of whether Vytorin causes cancer.
Vytorin is the controversial cholesterol lowering drug that is the center of a major advertising fraud that netted Merck and Schering-Plough over 10 billion dollars in sales in the past two years. Merck and Schering-Plough are facing congressional investigation, various state attorney general investigations, and plaintiff class action lawsuits. All the negative publicity has caused sales to fall off, yet the questionable drug is still a top seller for Merck and Schering-Plough in 2008.
Underneath the advertising fraud is a far more damaging prospect from the Big Pharma point of view, that the theory of lowering LDL cholesterol with drugs to prevent heart disease is itself a major fraud that has been perpetrated on the American public for the past decade. Indeed, while Vytorin is the most effective drug combination of all time in terms of lowering LDL, doing so does not produce cardiovascular health or reduce cardiovascular mortality.
A radioactive tracer that "lights up" cancer hiding inside dense breasts showed promise in its first big test against mammograms, revealing more tumors and giving fewer false alarms, doctors reported Wednesday.
Page 199 of 213